6.31
-0.17(-2.62%)
Currency In USD
| Previous Close | 6.48 |
| Open | 6.56 |
| Day High | 6.69 |
| Day Low | 6.26 |
| 52-Week High | 41.22 |
| 52-Week Low | 4.83 |
| Volume | 65,039 |
| Average Volume | 1.04M |
| Market Cap | 15.91M |
| PE | -0.49 |
| EPS | -12.93 |
| Moving Average 50 Days | 9.68 |
| Moving Average 200 Days | 11.49 |
| Change | -0.17 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $0.99 as of August 20, 2025 at a share price of $6.31. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $25.49 as of August 20, 2025 at a share price of $6.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
GlobeNewswire Inc.
Aug 05, 2025 8:00 PM GMT
Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development w
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire Inc.
Jul 30, 2025 12:05 PM GMT
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development o
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
GlobeNewswire Inc.
Jul 29, 2025 12:30 PM GMT
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on T